Literature DB >> 2197944

Menopause and heart disease. A review.

M J Stampfer1, G A Colditz, W C Willett.   

Abstract

A large number of studies of disparate design are reasonably consistent in demonstrating that women with early bilateral oophorectomy are at increased risk of coronary heart disease. The evidence for an increase in risk among women with a surgical menopause but without bilateral oophorectomy is inconclusive, but such an effect, if any, could plausibly be explained by decreased ovarian function in many of those women as a consequence of the surgery. These findings, taken together with the lack of excess risk in women with bilateral oophorectomy who take replacement estrogen, support the view that the increased risk is due to estrogen deficiency. This view is further supported by the improvement in the lipid profile induced by estrogen replacement therapy in postmenopausal women. Because ovarian function begins to decline well before menopause, and continues to decline after menopause, it is not surprising that the moment of menopause is not associated with an abrupt increase in risk of heart disease. Moreover, some time is required for the adverse changes in coronary risk factors that occur during the climacteric to be reflected in increased rates of coronary disease. Although natural menopause does not cause an immediate increase in risk of heart disease, it does signal a period of increasing risk that is probably related both to age and to estrogen deficiency.

Entities:  

Mesh:

Year:  1990        PMID: 2197944     DOI: 10.1111/j.1749-6632.1990.tb30329.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  17 in total

Review 1.  Risk factors for cardiovascular disease and hormone therapy in women.

Authors:  P Collins
Journal:  Heart       Date:  2006-05       Impact factor: 5.994

Review 2.  Management of lipid disorders in the elderly.

Authors:  D A Playford; G F Watts
Journal:  Drugs Aging       Date:  1997-06       Impact factor: 3.923

3.  Brain levels of sex steroid hormones in men and women during normal aging and in Alzheimer's disease.

Authors:  Emily R Rosario; Lilly Chang; Elizabeth H Head; Frank Z Stanczyk; Christian J Pike
Journal:  Neurobiol Aging       Date:  2009-05-09       Impact factor: 4.673

4.  Obesity and type 2 diabetes are associated with elevated PCSK9 levels in young women.

Authors:  Amy E Levenson; Amy S Shah; Philip R Khoury; Thomas R Kimball; Elaine M Urbina; Sarah D de Ferranti; David M Maahs; Lawrence M Dolan; R Paul Wadwa; Sudha B Biddinger
Journal:  Pediatr Diabetes       Date:  2017-01-17       Impact factor: 4.866

5.  Sex-specific impact of aging on the blood pressure response to exercise.

Authors:  Joel D Trinity; Gwenael Layec; Corey R Hart; Russell S Richardson
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-10-13       Impact factor: 4.733

Review 6.  Is gender a risk factor for adverse drug reactions? The example of drug-induced long QT syndrome.

Authors:  M D Drici; N Clément
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

7.  Hemostatic Factors and Ischemic Heart Disease Risk Among Postmenopausal Women.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

Review 8.  Management of hypercholesterolaemia in postmenopausal women.

Authors:  Michael H Davidson; Kevin C Maki; Sherry Katz Karp; Kate A Ingram
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

9.  [Effects of a structured exercise programme on cardiovascular risk programmes in post-menopausal women. CLIDERICA study].

Authors:  Pedro Saucedo Rodrigo; José Abellán Alemán; Purificación Gómez Jara; Mariano Leal Hernández; Enrique Ortega Toro; Juan Carlos Colado; Juan Carlos Colado Sánchez; Pilar Sáinz de Baranda Andújar
Journal:  Aten Primaria       Date:  2008-07       Impact factor: 1.137

10.  Longitudinal assessment of the effects of oestrogen on blood pressure and cardiovascular autonomic activity in female rats.

Authors:  Mahmoud M El-Mas; Abdel A Abdel-Rahman
Journal:  Clin Exp Pharmacol Physiol       Date:  2009-04-27       Impact factor: 2.557

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.